Q-omics provides the consensus-scored FBXW8 profile across patient tissues and cancer cell-line models. FBXW8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FBXW8 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, FBXW8 RNA expression shows 20,785 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRP, and ACC as cancer lineages where FBXW8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXW8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXW8 survival associations across molecular data types. FBXW8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXW8 RNA expression–survival associations across cancer types. High FBXW8 expression shows unfavorable associations in MESO, BLCA, LIHC and ACC, but favorable associations in UCS and SCLC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FBXW8 RNA expression.
This table summarizes FBXW8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXW8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXW8 shows lower tumor expression in THCA and higher tumor expression in KIRP, COAD, LIHC, HNSC and BRCA. The KIRP box plot shows higher FBXW8 RNA expression in tumor versus normal tissue (log2 FC = +1.108, t-test p < 0.001).
This table shows molecular features associated with FBXW8 in patient tissues and cancer cell lines. In patient samples, FBXW8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXW8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
